Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation

Author:

Mamas Mamas A.,Batson Sarah,Pollock Kevin G.,Grundy Sarah,Matthew Andrew,Chapman Chris,Manuel Joana Assis,Farooqui Usman,Mitchell Stephen A.

Funder

Bristol-Myers Squibb

Pfizer

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. The epidemiology of atrial fibrillation and stroke;Pistoia;Cardiol Clin,2016

2. National physician survey for nonvalvular atrial fibrillation (NVAF) anticoagulation comparing knowledge, attitudes, and practice of cardiologist to PCPs;Saeed;Clin Appl Thromb Hemost,2020

3. A systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation;Hill;Clin Appl Thromb Hemost,2020

4. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews;Page;Int J Surg,2021

5. Viswanathan M, Ansari M, Berkman N, Chang S, Hartling L, McPheeters L, Santaguida PL, Shamliyan T, Singh K, Tsertsvadze A, Treadwell JR. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. AHRQ Publication March 8, 2012.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3